AAIC 2025 Abstract·26 DecPRImus‐AD study: Design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer’s disease (AD) with the orally available PRI‐002Trial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecResults of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action.Trial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecAnti‐oligomeric PRI‐002 does not cause ARIA‐E in an ongoing Phase 2 trialTrial in peopleInterventionsPaper